Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

A Window into Health Disparities

Edward H. Yelin, PhD, MCP  |  Issue: October 2011  |  October 7, 2011

Systemic lupus erythematosus offers a touchstone for the U.S. healthcare system—and how we care for vulnerable patients

It is well known that systemic lupus erythematosus (SLE) disproportionately affects women and members of racial and ethnic minorities, and that persons with SLE of lower socioeconomic status have poorer outcomes of disease and higher death rates. The combination of SLE’s increased prevalence among minorities and women and its complexity, which leads to a need to have access to a wide range of healthcare services, makes SLE an important case study of how people of a racial or ethnic minority or another group facing discrimination or disadvantaged due to having low incomes fare in the U.S. healthcare system.

Researchers have long known that women and members of several racial and ethnic minorities have higher rates of SLE, particularly African-Americans, Asian-Americans, Native Americans, and Hispanics. Recent research has begun to identify genes and environmental triggers that may partially explain these differences.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

After diagnosis, the course of the SLE depends on many of the same factors that appear to contribute to the development of SLE in the first place. Evidence implicates genetic make-up, race/ethnicity, and socioeconomic status, particularly living in poverty. The persistence of differences in course of disease based on race/ethnicity and socioeconomic status has given rise to an increasing number of studies to help explain why such disparities exist. These studies have in turn led to efforts such as The Lupus Initiative, which is designed to reduce disparities in SLE outcomes. [See this month’s “President’s Perspective” for more on The Lupus Initiative.]

Several studies have attempted to discover whether the genetic aspects of race or the social aspects, such as being subjected to discrimination and having disproportionate poverty rates, accounts for the poor outcomes of minority groups.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The nature of our healthcare system probably also plays a role in the outcomes of vulnerable groups (more on why below). However, it clearly is not responsible for all of the effects of being a woman, member of a racial minority, or being in an economically disadvantaged position. We know this because in developed countries with universal health insurance coverage and good health systems, some of the same effects of gender, race/ethnicity, and poverty are seen—although it could be that the quality of care may not be optimal in any country, especially when it comes to treating vulnerable populations. In the U.S., many at-risk patients have access to insurance and the same experienced physicians and hospitals as more advantaged populations, yet still experience poorer outcomes.

Page: 1 2 3 4 | Single Page
Share: 

Filed under:ConditionsSystemic Lupus Erythematosus Tagged with:DisparitiesethnicityLupuspatient careraceSLE

Related Articles

    New Studies Examine Impact of Poverty, Race, Ethnicity in Patients with SLE

    October 17, 2017

    To correctly address a problem, one must have a handle on its nuances—a clear understanding of what is linked and how. And thus far, when it comes to lupus, we haven’t reached the point of understanding those intricacies. Things are heading in the right direction, however, with two new studies that get us much closer…

    New Findings on Rheumatic Drug Therapies among Patients with Ankylosing Spondylitis, Gout, SLE

    March 20, 2017

    WASHINGTON, D.C.—Taking high-dose non-steroidal anti-inflammatory drugs (NSAIDs) with a TNF inhibitor as an ankylosing spondylitis (AS) patient is linked with a 61% decrease in the chances your disease will progress, suggesting there may be a synergy when the drugs are used together, according to a longitudinal observational study from researchers at the University of California,…

    Racial Bias Found in Pain Assessment, Management, Treatment Recommendations by Clinicians

    October 10, 2016

    In the world of evidence-based medicine, basing diagnosis and treatment decisions on belief instead of data seems anachronistic. And yet … clinicians are human, and humans live in culture, and culture is formed by beliefs, and beliefs (consciously or unconsciously) drive perception and, often, action. So a new study shining a light on racial bias…

    Lupus often presents with a butterfly rash.

    Top 12: Research in Systemic Lupus Erythematosus at a Glance

    November 18, 2021

    Dr. Pisetsky’s picks for the top research in lupus presented at ACR Convergence 2021.

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences